Eli Lilly — Press Release
Lilly acquired Ajax to gain AJ1-11095, a Type II JAK2 inhibitor in Phase 1 for myelofibrosis and polycythemia vera. The drug has a unique binding mode potentially offering deeper, more durable responses than current JAK inhibitors. First proof-of-concept data expected in 2026.
